Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453736 | 1.00 | CYP26A1 (0.31) | CYP26A1ADRA1A | |
| SCHEMBL3453731 | 1.00 | CYP26A1 (0.31) | CYP26A1ADRA1A | |
| SCHEMBL3453865 | 0.91 | ADRA1A (0.32) | ADRA1A | |
| SCHEMBL3452841 | 0.90 | ROCK2 (0.34) | ADRA1A | |
| SCHEMBL3453539 | 0.89 | HSD11B1 (0.38) | CYP26A1ADRA1A | |
| SCHEMBL13109207 | 0.89 | MERTK (0.31) | — | |
| SCHEMBL3453421 | 0.88 | ADRA1A (0.30) | ADRA1A | |
| SCHEMBL3454743 | 0.88 | PTGS2 (0.32) | — | |
| SCHEMBL3454741 | 0.88 | PTGS2 (0.32) | — | |
| SCHEMBL3454747 | 0.88 | PTGS2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | claimed |
| US-7820659-B2 | Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-26 | — | — | US | claimed |
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | claimed |
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | CYP26A1 69/4885ADRA1A 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.